Awasthy BS, Julka PK, Rath GK. Medulloblastoma – A retrospective analysis. Ind J Pediat 1998.
Awasthy BS, Julka PK, Aggarwal S, Nair O, Bhamrah R, Rath GK. Effect of amifostine on toxicities associated with salvage combination chemotherapy. J Assoc Physicians India. 2001: 49;236-9
Bansal M, Mohanti BK. Sentinel lymph node biopsy, axillary dissection and breast cancer Radiation Oncologist’s viewpoint. Natl Med J India. 2002; 15: 154-57.
Bharanidharan G, Durai K, Subramani V, Gopishankar N, Ganesh T etal. characterization of responses and comparison of calibration factors for commercial MOSFEt detectors. Med Dosim 2005;30:213.
Biswal BM, Mohanti BK, Rath GK, Kumar L, Kriplani A, Ganesh T, Takkar D, Kumar S. Results of radical radiotherapy in carcinoma of the uterine cervix stage I-III. Clin. Oncol. 1994; 6:356-360.
Biswal BM, Lal P, Rath GK, Shukla NK, Mohanti BK, Deo SVS. Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother. Oncol. 1995; 35:212-215
Chander S, Datta NR, Singh K, and Rath GK. Evaluation of electron beam irradiation technique in Indian breast carcinoma patients. Ind J Med Sci 1990;44:143-147.
Chander S, Gupta MR, Rath GK et al. Low dose rate transperineal template Brachytherapy in for carcinoma cervix. J Brachyther Int 1999; 15 (3):
D’Souza H, Joshi RC, Ganesh T, Subramani V, Vasu G, Kumar R, Julka PK and Rath GK Variation in the isocentre of a Philips Linear Accelerator (SL-20) used for stereotactic radiosurgery/ stereotactic radiotherapy. Australian Radiology. 1999; 43(3), 342-345.
Ganesh T, Sharma S, Joshi RC, Singhal S, Shahi UP, Kumar R, Rath GK. Calculation of Reference Volume from Total Reference Air Kerma:A simple procedure. J Int Fed Med Biol Eng 1991;29 supp 2 :1229
Majhail N S, Chander S, Mehta V S, Julka P K, Gansesh T, Rath G K. Factors influencing early complications following gama knife radiosurgery. Stereotact funet Neurosurg. 2001;76:36.
Julka PK, Awasthy BS, Rath GK, Aggarwal S, Varna T, Mahapatra AK, Singh R. Study of concurrent radiochemotherapy with Paclitaxel in Glioblastoma Multiforme. Australasian Radiology. 2000; 44, 84-87.
Julka PK, Sharma DN, Mukhopadhyay P, Rath GK. Trastuzumab and docetaxel in metastatic breast cancer. Clin Oncol. 2004; 16:115-118.
Mohanti BK, Shukla NK, Chawla S, Ganesh T et al. Experience with intraluminal radiotherapy in advanced oesophageal cancer. Trop. Gastroenterol. 1995; 16:27-32.
Mohanti BK, Tandon DA, Bahadur S, Rath GK, Tanwar RK, Lal P and Biswal BM. Results of definitive radiotherapy in T1 and T2 glottic carcinoma : Institute of Rotary Cancer Hospital experience. Australasian Radiol. 1996; 40;287-290.
Mohanti BK, Rath GK, Anantha N, Kannan V et al. Improving cancer radiotherapy with 2-deoxy-d-glucose: Phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat Oncol. Biol. Phys. 1996; 35:103-111.
Mohanti BK, Swami K, Ganesh T, Lal P, Biswal BM, Joshi RC, D’Souza H and Rath GK. Iridium-192 interstitial brachytherapy in carcinoma of the tongue. Acta Oncol. 1997; 36:165-169.
Mohanti B K, Nachiappan P, Pandey R M, Sharma et al. Analysis of 2167 head and neck cancer patients management, treatment compliance and outcomes from a regional cancer centre, Delhi, India. J. Laryngol otol:2006, 1-8.
Mohanti B K, Bansal M. Review late sequelae of radiotherapy in adults. Support care cancer 2005;13:775-80.
Mohanti BK. Radiotherapy in malignant gliomas. Editorial. The Cancer J. 1997; 10:3-4.
Mohanti BK, Bansal M, Bahadur S, Shukla NK, Prabhakar R et al.. Interstitial brachytherapy with or without external beam irradiation in head and neck cancer: Institute Rotary Cancer Hospital experience. Clin Oncol. 2001;13: 345-52.
Parida DK, Verma KK, Chander S, Joshi RC, Rath GK. Cutaneous T-Cell lymphoma treated with electron beam irradiation in Indian patients. Int J Dermatol 2001;40:295-297.
Rath GK, Chander S, De S, Kumar R. Total Skin Electron irradiation for mycosis fungoides. Ind J Cancer 1986; 23: 146-50.
Rath GK, Chander S, Grover R. Unveiling the multifarious developments in the treatment of cervical cancer for over a centenary. JIMA 1995;93(11):425-427.
Rath GK, Deo SVS. Consensus on oral cancer management-AIIMS perspective. Asian Pac J Cancer Prev 2000;1:117-118
Rath GK, Syed AMN, Gopi S et al. “INDIRA” Trial: De novo low dose rate intracoronary irradiation after angioplasty and stent placement for prevention of restenosis. J Brachyth Int 2001;17:317-330.
Rath GK, Sharma DN, Julka PK. ICRU report 38: has the radiation oncology community accepted it? International Commission on Radiation Units & Measurements. Clin Oncol 2002;14(5):430-1
Sharma DN, Chawla S, Gairola M, Mohanti BK, Deo SVS, Shukla NK, Rath GK. Biliary tract neoplasms. Trop. Gastroenterol. 1998; 19:56-58.
Sharma DN. Gairola M, Mohanti BK, Rath GK. Radiation Therapy in skeletal metastasis. Med. J. Malaysia. 1999; 54: 210-215.
Sharma DN, Chander S, Gairola M, Kumar S, Kumar L, Rath G K. Intravaginal Brachytherapy alone and in combination to external beam radiation therapy in the postoperative management of FIGO stage I-II endometrial carcinoma. J Brachyther Int 2000; 16: 173-180.
Sharma S, Singhal S, De S, Chander S, Rath G K, Misra A and Khosla A. Primary Gastric Lymphoma: A Prospective Analysis of 12 cases and Review of the Literature. J Surg Oncol 1990; 43: 231-238.
Sharma U., Robert S.M., Julka P.K. and Parameswaran T.: Primary Bone Lymphoma (1986). Ind. J.Cancer, 23:157-162.
Singh RK, Parida DK, Mohanti BK, Rath GK. Preoperative Radiotherapy for squamous cell carcinoma of the esophagus. Int J Surg Inv. 2001; 3:401-6.
S Pathy, S Jayalakshmi, S Chander, R Singh, P K Julan, G K Rath Prognostic Factors influencing the outcome of thalmic glioma. Neurology India 50. March 2002;37-40
B Mohanti, H Umapahty, S Bahadur, A, Thakar, S Pathy Short Course Palliative Radiotherapy of 20 gy in 5 fractions fro advanced and incurable head and neck cancer AIIMS study radiotherapy Oncol 71, (2004) 275-280.
Adjuvant Tamoxifen-Longer Against Shorter (ATLAS).
A phase III study of Gemcitabine plus Paclitaxel versus Paclitaxel in patients with unresectable, locally recurrent or metastatic breast cancer. B0E-MC-JHQG.
A phase 3 trial of Alimta Vs Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy.
A randomized, controlled, open label study to evaluate the efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor Arimidex® (anastrozole) compared with Arimidex® alone as first and second line treatment administered to postmenopausal, hormone receptor positive (ER+ve and/or PR+ve) patients with HER2 overexpressing metastatic breast cancer.
Multicenter Phase III randomized trial comparing doxorubicin and Cyclophosphamide followed by Docetaxel (AC--t) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (Erceptin) (AC--TH) and with Docetaxel, Carboplatin and Trastuzumab (TCH) in the Adjuvant treatment of node positive and high risk node negative patients with operable Breast cancer containing the HER2 alteration.
A centrally randomized, open multi-center study evaluating the efficacy and safety of combination therapy with Intermax alphaTM and vinblastine versus vinblastine monothreapy in patients with Advanced Cell Carcinoma
A Phase 2 study of Sequential Neoadjuvant Gemcitabine Plus Doxorubicin and Gemcitabine Plus Cisplatin in Large T2 ( 3cm) and Locally Advanced (T3 T4 or N2) Operable Breast Cancer"
A Randomized, double blind, placebo control, phase II study of oral recombinant human lactoferrin (rhLF) in combination with carboplatin and paclitaxel (C/P) chemotherapy in patients with locally advanced and/or metastatic non-small-cell lung cancer (NSCLC)
International Multicenter Trial funded by IAEA, Vienna titled “ A randomized study of 5 versus 6 weekly fractions of radiotherapy in the treatment of squamous cell carcinoma of the Head and Neck – Aspects of radiobiology applicable in clinical radiotherapy – increase of the number of fractions per week. IAEA-CRP.E.3.30.18
Concurrent chemo-radiotherapy for oropharyngeal and hypopharyngeal cancers.
Concurrent chemo-radiotherapy as postoperative adjuvant therapy in operable stomach and hepatobiliary neoplasms.
RT ward : 32 beds
|Name of the OPD||Day & Time||Special Instruction|
|Radiotherapy Evaluation||Tuesday & Friday 9 A.M||Patients are generally seen On referral with confirmed Histopathology|